Literature DB >> 7974380

Measurement of thrombin generation in whole blood--the effect of heparin and aspirin.

H Kessels1, S Béguin, H Andree, H C Hemker.   

Abstract

A technique has been developed to monitor the development of thrombin in freshly collected whole blood in the absence of anticoagulants. It is based on the centrifugal separation of the cellular components from subsamples of blood drawn from non-anticoagulated clotting whole blood which are diluted in buffer containing a chromogenic substrate. It is shown that the burst of thrombin generation after triggering coagulation with trace amounts of tissue thromboplastin occurs sooner in non-anticoagulated whole blood than in citrated whole blood. Heparin is shown to prolong the lag-time of thrombin generation more in native blood than in recalcified citrated blood. It is also demonstrated that intake of 500 mg of aspirin significantly delays and inhibits thrombin generation in non-anticoagulated, thromboplastin triggered whole blood, whereas it has no effect on the coagulation in citrated plasma. The effect of aspirin intake on thrombin generation in blood is roughly equal to that of 0.03 U/ml of unfractionated heparin. This demonstrates that platelet reactions and the coagulation system are closely linked processes. It further lends support to the hypothesis that inhibition of thrombin generation is a common denominator of antithrombotic therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7974380

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  16 in total

1.  Thromboprophylaxis after replacement arthroplasty.

Authors:  D P Thomas
Journal:  BMJ       Date:  2001-03-24

Review 2.  Aspirin in patients with coronary artery disease: is it simply irresistible?

Authors:  G V Nair; C J Davis; M E McKenzie; D R Lowry; V L Serebruany
Journal:  J Thromb Thrombolysis       Date:  2001-04       Impact factor: 2.300

Review 3.  Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.

Authors:  John W Eikelboom; Jack Hirsh; Frederick A Spencer; Trevor P Baglin; Jeffrey I Weitz
Journal:  Chest       Date:  2012-02       Impact factor: 9.410

4.  Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".

Authors:  J C Reverter; S Béguin; H Kessels; R Kumar; H C Hemker; B S Coller
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

5.  Aspirin resistance and diabetes mellitus.

Authors:  R Ajjan; R F Storey; P J Grant
Journal:  Diabetologia       Date:  2008-03       Impact factor: 10.122

Review 6.  Antithrombotic properties of aspirin and resistance to aspirin: beyond strictly antiplatelet actions.

Authors:  Anetta Undas; Kathleen E Brummel-Ziedins; Kenneth G Mann
Journal:  Blood       Date:  2006-12-05       Impact factor: 22.113

7.  Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis.

Authors:  P A Von dem Borne; L Bajzar; J C Meijers; M E Nesheim; B N Bouma
Journal:  J Clin Invest       Date:  1997-05-15       Impact factor: 14.808

8.  Proteolytically activated anti-bacterial hydrogel microspheres.

Authors:  Jason S Buhrman; Laura C Cook; Jamie E Rayahin; Michael J Federle; Richard A Gemeinhart
Journal:  J Control Release       Date:  2013-06-28       Impact factor: 9.776

Review 9.  Antiplatelet drugs. A comparative review.

Authors:  K Schrör
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

10.  Interconnectedness of global hemostasis assay parameters in simultaneously evaluated thrombin generation, fibrin generation and clot lysis in normal plasma.

Authors:  Kevin Z Xin; William C Chang; Mikhail V Ovanesov
Journal:  Thromb Res       Date:  2015-11-19       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.